Trial · NCT03395977
Uric Acid Effects on Endothelium and Oxydative Stress
NCT03395977, Not applicable, Completed, Erasme University Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Uric Acid Effects on Endothelium and Oxydative Stress. Trials, record NCT03395977. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03395977
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Uric Acid Effects on Endothelium and Oxydative Stress
- NCT number
- NCT03395977
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 53 participants, actual
- Lead sponsor
- Erasme University Hospital
- Conditions
- Oxidative Stress, Endothelial Function, Cardiovascular System, Hypertension
- Interventions
- Placebos, Febuxostat, Rasburicase
- First posted
- 2018-01-10
- Last updated
- 2020-02-28
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cutaneous perfusion by Laser Doppler (perfusion unit) | 24 hours after infusion of Uricase or Placebo | Perfusion unit (Laser Doppler Imager + iontophoresis of (ACh and SNP and hyperemia with ou without L-NAME). Assessment of endothelial function. |
| Secondary | Change in Oxydative stress biomarkers from baseline to 30 min or 24 hours after infusion of Uricase or Placebo | Baseline, 30 minutes and 24 hours after infusion of Uricase or Placebo | |
| Secondary | Arterial stiffness | 24 hours after infusion of Uricase or Placebo | Carotido-femoral and carotido-radial pulse wave velocity and pulse wave analysis |
| Secondary | Blood pressure (mmHg) | 24 hours after infusion of Uricase or Placebo | Beat-to-beat measurements with Finapres and manually |
| Secondary | Cardiac output (l-min) | 24 hours after infusion of Uricase or Placebo | Beat-to-beat measurements with Finapres |
| Secondary | Change in enzymes activity | 30 min and 24 hours after infusion of Uricase or Placebo | Xanthin oxydase activity |
| Secondary | Change in enzymes expression | 30 min and 24 hours after infusion of Uricase or Placebo | eNOS, NOX, XO we will incubate endothelial cells with plasma or serum from subjects. Then we will measure the sus-mentionned enzymes' expression. |
| Secondary | Change in proteomic or metabolomic analysis | 30 min and 24 hours after infusion of Uricase or Placebo | We will perform proteomics or metabolomics analysis directly on serum from participants and also on lysate of endothelial cells pre-incubated with plasma or serum from participants. |
| Secondary | Change in renin-angiotensin activity | Baseline, 30 minutes and 24 hours after infusion of Uricase or Placebo | |
| Secondary | Change in urinary excretion of sodium | Baseline, 30 minutes and 24 hours after infusion of Uricase or Placebo |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03395977
GET https://conductscience.org/api/trials/v1/NCT03395977/registered